McKesson Sells Stake to Apollo: Strategic IPO Move

McKesson Corporation (MCK) has divested a minority stake in its medical-surgical solutions division to Apollo Funds in a $1.25 billion transaction as the company prepares for a spinoff via initial public offering. This deal enables McKesson to extract value while concentrating on higher-growth oncology and biopharma services, setting up both companies for strategic autonomy.

Key Takeaways

Apollo Funds acquires minority stake for $1.25 billion
Medical-surgical unit generated $11.4 billion revenue in fiscal 2025
IPO planned for second half of 2027

Strategic Portfolio Optimization

This transaction demonstrates McKesson’s focused capital allocation approach, directing resources toward higher-margin prospects in oncology and biopharma solutions¹. While the medical-surgical solutions division accounts for just 3.2% of McKesson’s overall revenue, it has faced tepid growth since 2020 due to post-pandemic normalization and supply chain challenges².

McKesson CEO Brian Tyler stated the separation will “unlock significant value for both McKesson and Medical-Surgical Solutions, enabling each to pursue growth and operational excellence in their respective markets”³. The company has demonstrated expertise in successful divestitures previously, including Change Healthcare in 2020, which generated considerable shareholder value.

Financial Performance and Market Context

The medical-surgical division posted $11.4 billion in revenue for fiscal year 2025, marking a modest 1% increase from the previous year¹. Operating profit margins have remained solid despite volume challenges, especially in physician office environments and seasonal illness patterns⁴.

McKesson’s overall portfolio showed robust performance, with total revenues reaching $359.1 billion in fiscal 2025, climbing 16.2% year-over-year². The company’s U.S. Pharmaceutical division, accounting for 91.3% of sales, powered much of this expansion through enhanced specialty drug distribution, particularly in oncology treatments.

IPO Timeline and Market Preparation

The company aims for an IPO of the medical-surgical division during the second half of calendar year 2027, contingent on market conditions and regulatory clearances⁴. Critical transition service agreements were finalized on January 1, representing a significant milestone toward operational autonomy.

McKesson leadership highlighted their proven ability with complex separations, including recent successful exits from European markets through the divestiture of Norwegian operations to NorgesGruppen⁴. The company anticipates the separated entity will gain from focused management attention and customized growth strategies across alternate care markets.

Investment in Growth Areas

Alongside the medical-surgical divestiture, McKesson has bolstered its oncology platform through a $2.49 billion acquisition of a 70% stake in CORE Ventures, supporting over 250 physicians across nearly 100 locations in Florida³. This investment supports the company’s strategy to channel resources into high-growth specialty sectors.

The company projects fiscal 2026 adjusted earnings per share of $36.75 to $37.55, indicating 11% to 14% growth year-over-year². Management confirmed long-term adjusted EPS growth objectives of 12% to 14% while revising U.S. Pharmaceutical segment operating profit growth expectations to 6% to 8%.

Not investment advice. For informational purposes only.